{"data":[{"accessionNo":"0000315066-26-002326","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS INC","ticker":"XFOR","cusip":"98420X202","securityClass":"COMMON STOCK","eventDate":"2026-09-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":4558616,"percentOfClass":4.6,"filedAt":"2026-10-07","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000315066-26-002326","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS INC","ticker":"XFOR","cusip":"98420X202","securityClass":"COMMON STOCK","eventDate":"2026-09-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":4558616,"percentOfClass":4.6,"filedAt":"2026-10-07","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001738048-26-000071","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-09-14","reportingPerson":"Venrock Healthcare Capital Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5555047,"percentOfClass":5.6,"filedAt":"2026-09-21","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001738048-26-000071","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-09-14","reportingPerson":"VHCP Co-Investment Holdings III, LLC","reportingCik":null,"personType":"OO","sharesOwned":5555047,"percentOfClass":5.6,"filedAt":"2026-09-21","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001738048-26-000071","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-09-14","reportingPerson":"Venrock Healthcare Capital Partners EG, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5555047,"percentOfClass":5.6,"filedAt":"2026-09-21","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001738048-26-000071","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-09-14","reportingPerson":"VHCP Management III, LLC","reportingCik":null,"personType":"OO","sharesOwned":5555047,"percentOfClass":5.6,"filedAt":"2026-09-21","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001738048-26-000071","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-09-14","reportingPerson":"VHCP Management EG, LLC","reportingCik":null,"personType":"OO","sharesOwned":5555047,"percentOfClass":5.6,"filedAt":"2026-09-21","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001738048-26-000071","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-09-14","reportingPerson":"Nimish Shah","reportingCik":null,"personType":"IN","sharesOwned":5555047,"percentOfClass":5.6,"filedAt":"2026-09-21","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001738048-26-000071","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-09-14","reportingPerson":"Bong Y. Koh","reportingCik":null,"personType":"IN","sharesOwned":5555047,"percentOfClass":5.6,"filedAt":"2026-09-21","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001172661-26-003487","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":8040894,"percentOfClass":8.33,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001172661-26-003487","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":8040894,"percentOfClass":8.33,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-352651","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":8085006,"percentOfClass":8.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-352651","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":8085006,"percentOfClass":8.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-352651","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":8085006,"percentOfClass":8.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001172661-26-003487","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":6923680,"percentOfClass":7.18,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001172661-26-003487","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Deep Track Special Opportunities Fund, LP.","reportingCik":null,"personType":"PN","sharesOwned":1117214,"percentOfClass":1.16,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0002012383-26-003133","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS INC","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":5529573,"percentOfClass":5.9,"filedAt":"2026-07-30","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-226568","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":6889163,"percentOfClass":7.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-226568","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":6889163,"percentOfClass":7.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-226568","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":"98420X202","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":6889163,"percentOfClass":7.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000895421-26-000094","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock","eventDate":"2026-02-28","reportingPerson":"Morgan Stanley","reportingCik":null,"personType":"HC,CO","sharesOwned":8884338,"percentOfClass":10.2,"filedAt":"2026-03-06","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000895421-26-000094","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock","eventDate":"2026-02-28","reportingPerson":"Morgan Stanley Investment Management Inc.","reportingCik":null,"personType":"IA,CO","sharesOwned":8884304,"percentOfClass":10.2,"filedAt":"2026-03-06","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000895421-26-000094","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock","eventDate":"2026-02-28","reportingPerson":"Inception Trust","reportingCik":null,"personType":"IA,CO","sharesOwned":4518236,"percentOfClass":5.2,"filedAt":"2026-03-06","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-054779","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BCLS II Equity Opportunities, LP","reportingCik":null,"personType":"PN","sharesOwned":7047216,"percentOfClass":7.43,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-26-016241","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock","eventDate":"2025-10-24","reportingPerson":"Xiaoying Tian","reportingCik":null,"personType":"IN","sharesOwned":6433481,"percentOfClass":7.36,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-26-016241","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock","eventDate":"2025-10-24","reportingPerson":"Saturn V Capital Management LP","reportingCik":null,"personType":"IA","sharesOwned":6433481,"percentOfClass":7.36,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001493152-26-007144","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Ortav Yehudai","reportingCik":null,"personType":"IN","sharesOwned":5227222,"percentOfClass":5.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001493152-26-007144","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Trails Edge Capital Partners, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":5227222,"percentOfClass":5.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001493152-26-007144","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Trails Edge Biotechnology Master Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":5227222,"percentOfClass":5.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000921895-26-000476","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":3411993,"percentOfClass":3.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000921895-26-000476","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":3411993,"percentOfClass":3.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000921895-26-000476","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":3411993,"percentOfClass":3.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000921895-26-000476","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":3166514,"percentOfClass":3.6,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000921895-26-000476","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":1827005,"percentOfClass":2.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000921895-26-000476","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1827005,"percentOfClass":2.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000921895-26-000476","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1339509,"percentOfClass":1.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000921895-26-000476","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":1339509,"percentOfClass":1.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-054779","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BCLS II Investco, LP","reportingCik":null,"personType":"PN","sharesOwned":758598,"percentOfClass":0.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000921895-26-000476","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":194535,"percentOfClass":0.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000921895-26-000476","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":194535,"percentOfClass":0.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-054779","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BCLS I Investco, LP","reportingCik":null,"personType":"PN","sharesOwned":89633,"percentOfClass":0.09,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-054779","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Bain Capital Life Sciences Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":64190,"percentOfClass":0.07,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-054779","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BCIP Life Sciences Associates, LP","reportingCik":null,"personType":"PN","sharesOwned":7817,"percentOfClass":0.01,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-26-054779","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Bain Capital Life Sciences Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-26-015354","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":2449468,"percentOfClass":2.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-26-015354","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":2449468,"percentOfClass":2.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-26-015354","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":2449468,"percentOfClass":2.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000895421-26-000068","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Morgan Stanley","reportingCik":null,"personType":"HC,CO","sharesOwned":8196489,"percentOfClass":9.4,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000895421-26-000068","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Morgan Stanley Investment Management Inc.","reportingCik":null,"personType":"IA,CO","sharesOwned":8196455,"percentOfClass":9.4,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000315066-26-000584","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-10-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":8499100,"percentOfClass":9.7,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000315066-26-000584","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-10-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":8499100,"percentOfClass":9.7,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000902664-26-000246","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Empery Asset Management, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":9043894,"percentOfClass":9.99,"filedAt":"2026-01-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000902664-26-000246","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Ryan M. Lane","reportingCik":null,"personType":"HC,IN","sharesOwned":9043894,"percentOfClass":9.99,"filedAt":"2026-01-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-25-112658","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":2244319,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-25-112658","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":2244319,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-25-112658","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":2244319,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000315066-25-002923","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS INC","ticker":"XFOR","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-10-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":8499100,"percentOfClass":14.8,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000315066-25-002923","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS INC","ticker":"XFOR","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-10-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":8499100,"percentOfClass":14.8,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-25-262560","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":6064680,"percentOfClass":7.6,"filedAt":"2025-11-03","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-25-262560","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":6064680,"percentOfClass":7.6,"filedAt":"2025-11-03","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-25-262560","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":6064680,"percentOfClass":7.6,"filedAt":"2025-11-03","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Growth Equity Opportunities 18 VGE, LLC","reportingCik":"0001917895","personType":"OO","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"NEA 18 Venture Growth Equity, L.P.","reportingCik":"0001880239","personType":"PN","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"NEA Partners 18 VGE, L.P.","reportingCik":"0001898446","personType":"PN","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"NEA 18 VGE GP, LLC","reportingCik":"0001898598","personType":"OO","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Ali Behbahani","reportingCik":"0001613867","personType":"IN","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Carmen Chang","reportingCik":"0001746342","personType":"IN","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Anthony A. Florence, Jr.","reportingCik":"0001559827","personType":"IN","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Mohamad H. Makhzoumi","reportingCik":"0001630226","personType":"IN","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Edward T. Mathers","reportingCik":"0001328625","personType":"IN","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Scott D. Sandell","reportingCik":"0001237289","personType":"IN","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Paul Walker","reportingCik":"0001553150","personType":"IN","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001072613-25-000747","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-27","reportingPerson":"Rick Yang","reportingCik":"0001851328","personType":"IN","sharesOwned":5057610,"percentOfClass":6.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000902664-25-004474","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Empery Asset Management, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":2498162,"percentOfClass":9.99,"filedAt":"2025-10-21","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000902664-25-004474","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Lane Ryan M.","reportingCik":null,"personType":"HC,IN","sharesOwned":2498162,"percentOfClass":9.99,"filedAt":"2025-10-21","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0000902664-25-004474","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Hoe Martin D.","reportingCik":null,"personType":"HC,IN","sharesOwned":2498162,"percentOfClass":9.99,"filedAt":"2025-10-21","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-25-096741","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-03","reportingPerson":"Coastlands Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":2491638,"percentOfClass":9.99,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-25-096741","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-03","reportingPerson":"Coastlands Capital Partners LP","reportingCik":null,"personType":"PN","sharesOwned":2491638,"percentOfClass":9.99,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-25-096741","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-03","reportingPerson":"Coastlands Capital GP LLC","reportingCik":null,"personType":"OO","sharesOwned":2491638,"percentOfClass":9.99,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-25-096741","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-03","reportingPerson":"Coastlands Capital LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":2491638,"percentOfClass":9.99,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001104659-25-096741","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 Pharmaceuticals, Inc.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-10-03","reportingPerson":"Matthew D. Perry","reportingCik":null,"personType":"HC,IN","sharesOwned":2491638,"percentOfClass":9.99,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-25-203640","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-09","reportingPerson":"Bain Capital Life Sciences Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2436588,"percentOfClass":9.99,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-25-203640","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-09","reportingPerson":"Bain Capital Life Sciences Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2436588,"percentOfClass":9.99,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-25-203640","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-09","reportingPerson":"BCIP Life Sciences Associates, LP","reportingCik":null,"personType":"PN","sharesOwned":2436588,"percentOfClass":9.99,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-25-203640","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-09","reportingPerson":"BCLS II Investco, LP","reportingCik":null,"personType":"PN","sharesOwned":2436588,"percentOfClass":9.99,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-25-203640","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-09","reportingPerson":"BCLS I Investco, LP","reportingCik":null,"personType":"PN","sharesOwned":2436588,"percentOfClass":9.99,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"},{"accessionNo":"0001193125-25-203640","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001501697","issuerName":"X4 PHARMACEUTICALS, INC.","ticker":"XFOR","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-09","reportingPerson":"BCLS II Equity Opportunities, LP","reportingCik":null,"personType":"PN","sharesOwned":2436588,"percentOfClass":9.99,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/xfor"}],"updatedAt":"2026-11-04T01:22:53.577Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/xfor","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}